NasdaqGM - Nasdaq Real Time Price USD

Ocular Therapeutix, Inc. (OCUL)

7.22

+0.05

+(0.70%)

At close: May 16 at 4:00:01 PM EDT

7.37

+0.15

+(2.08%)

After hours: May 16 at 6:02:13 PM EDT

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025. 2025 RBC Capital Markets Global Healthcare Conference, May 20, 2025 Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 2:35PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and C

GlobeNewswire 2 days ago

OCUL
+0.70%
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

One thing we could say about the analysts on Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) - they aren't optimistic, having...

Simply Wall St. 9 days ago

OCUL
+0.70%
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations

Ocular Therapeutix ( NASDAQ:OCUL ) First Quarter 2025 Results Key Financial Results Revenue: US$10.7m (down 28% from 1Q...

Simply Wall St. 10 days ago

OCUL
+0.70%
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.59% and 37.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 days ago

OCUL
+0.70%
Ocular Therapeutix: Q1 Earnings Snapshot

BEDFORD, Mass. AP) — Ocular Therapeutix Inc. OCUL) on Monday reported a loss of $64.1 million in its first quarter.

Associated Press Finance 11 days ago

OCUL
+0.70%
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected

GlobeNewswire 11 days ago

OCUL
+0.70%
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 17 days ago

ESPR

OCUL
+0.70%
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President

GlobeNewswire 17 days ago

OCUL
+0.70%
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information

GlobeNewswire 18 days ago

OCUL
+0.70%
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incent

GlobeNewswire last month

OCUL
+0.70%
Ocular Therapeutix™ to Participate in Two Investor Conferences in April

BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: 24th Annual Needham Virtual Healthcare ConferencePresentation Date: Monday, April 7, 2025Presentation Time: 3:00 PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Virtual Piper Sandler Spring Biopharma

GlobeNewswire last month

OCUL
+0.70%
Why Ocular Therapeutix Was Bumping Higher This Week

The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher. As of Friday morning before market open, the eye care specialist's shares were up by nearly 5% in price week to date, according to data compiled by S&P Global Market Intelligence. Early Tuesday morning, Needham's Serge Belanger formally became an Ocular analyst.

Motley Fool 2 months ago

OCUL
+0.70%
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD). Axpaxli is the company’s key value driver and is under evaluation in two phase 3 trials. If positive, these trials could support approval with a product label that enables maintenance treatment with Q6M (every 6 months)-Q12M (every 12 months) dosing, which would represent a signific

Benzinga 2 months ago

OCUL
+0.70%
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Ocular Therapeutix Inc (OCUL) showcases strong financial health and strategic trial advancements, positioning AXPAXLI for expanded market opportunities.

GuruFocus.com 2 months ago

OCUL
+0.70%
Q4 2024 Ocular Therapeutix Inc Earnings Call

Q4 2024 Ocular Therapeutix Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

OCUL
+0.70%
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -20.83% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

OCUL
+0.70%
Ocular Therapeutix: Q4 Earnings Snapshot

BEDFORD, Mass. AP) — Ocular Therapeutix Inc. OCUL) on Monday reported a loss of $48.4 million in its fourth quarter.

Associated Press Finance 2 months ago

OCUL
+0.70%
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional

GlobeNewswire 2 months ago

OCUL
+0.70%
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

OCUL
+0.70%
Ocular Therapeutix™ to Present at Two Investor Conferences in March

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March: TD Cowen 45th Annual Health Care Conference Presentation DetailsFireside Chat Date: Tuesday, March 4, 2025Fireside Chat Time: 11:50 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Leerink P

GlobeNewswire 2 months ago

OCUL
+0.70%

Performance Overview

Return	OCUL	S&P 500 (^GSPC)
YTD	-15.46%	+1.30%
1-Year	+15.15%	+12.48%
3-Year	+114.88%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Why Ocular Therapeutix Was Bumping Higher This Week

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Q4 2024 Ocular Therapeutix Inc Earnings Call

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Ocular Therapeutix™ to Present at Two Investor Conferences in March

Performance Overview